Thermo Fisher Scientific Inc. (TMO) recently announced a partnership with the National Cancer Institute (“NCI”) for the myeloMATCH (Molecular Analysis for Therapy Choice) precision medicine umbrella trial.Under the trial, patients’ bone marrow and blood will be tested for certain genetic biomarkers using Thermo Fisher’s next-generation sequencing (“NGS”) technology. With this, clinical sites can quickly match patients with an appropriate clinical trial that tests a treatment designed to target specific muta ...